Savara Splits CFO Role Amid Leadership Transition

Event summary

  • Dave Lowrance, Savara's Chief Financial and Administrative Officer, is stepping down effective July 15, 2026, for health reasons.
  • The company is splitting his role into two: Robert Lutz will become Chief Financial Officer, while administrative duties will be distributed among senior leaders.
  • Lutz, currently Chief Operating Officer, has over two decades of pharmaceutical industry experience, including prior CFO roles at iBio and Strongbridge Biopharma.
  • Lowrance served nearly a decade at Savara, guiding capital raises, Nasdaq listing, and late-stage pipeline development.

The big picture

This transition comes as Savara navigates critical late-stage development for its lead program, MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. The split of financial and administrative duties suggests a strategic realignment to better manage the company's growing operational complexity. The move reflects broader trends in biopharmaceutical leadership, where specialized roles are increasingly favored over combined positions to enhance focus and accountability.

What we're watching

Operational Continuity
How the distributed administrative responsibilities will impact decision-making efficiency and cross-functional coordination.
Financial Stewardship
Whether Robert Lutz can maintain strong financial governance while managing both COO and CFO responsibilities.
Strategic Momentum
The pace at which Savara advances its late-stage pipeline under the new leadership structure.